The Scientist I/II will report to the Neurology Program Lead and will work as part of a multidisciplinary team on drug development efforts to modulate activities of targets identified by Berg Interrogative Biology® Platform and on evaluating efficacy of novel drug candidates for Parkinson’s and other neurodegenerative diseases.
- Develop cell-based and biochemistry assays for phenotypic screens (low to medium throughput) and potency assays to validate novel drug candidates.
- Design and execute in vitro studies to demonstrate compound pharmacodynamics and support development of early drug candidates and lead molecules.
- Generate and utilize molecular biology reagents (including CRISPR gene-editing tools) for mechanism of action studies and to develop screening models.
- Critically analyze data and communicate findings effectively to multidisciplinary team members and management.
- Perform the full spectrum of laboratory activities including experimental design, assay development, and manage deliverables.
- Requires a PhD in neuroscience, pharmacology, biochemistry, or related fields with 0-2 years of postdoctoral training or MS with 5-7 years of experience in a pharma industry setting.
- Broad understanding in mechanisms of disease particularly in the areas of Parkinson’s disease and neurodegeneration in general. • Proven track-record of scientific achievement.
- Strong laboratory skills, particularly in the areas of molecular biology, biochemistry, and cell-based assays.
- Experience with pluripotent stem cells and differentiation protocols are required.
- Demonstrated ability to work in an interdisciplinary team and experience supervising and training technical staff.
- Strong work ethic and excellent oral/written communication skills are essential.